3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
6
Waldenstrom Macroglobulinemia
2
Recurrence
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Leukemia, B-Cell
2
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma
1
Hematologic Diseases
1
Chromosome 17 deletion
1
Interventions
Cyclophosphamide
2
zanubrutinib
1
ruxolitinib
1
pirtobrutinib
1
idecabtagene vicleucel
1
ibrutinib
1
fludarabine
1
acalabrutinib
1
Sirolimus
1
Semen Analysis
1
Physical Examination
1
Mycophenolic Acid
1
Leukapheresis
1
Lenalidomide
1
Cyclosporins
1
Cyclosporine
1
CPI-0610
1
Blood Specimen Collection
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Diseases
×
pirtobrutinib
×
30 days
×
Clear all
NCT04662255
2026-05-15
BRUIN-MCL-321
Eli Lilly and Company
Phase 3
Active not recruiting
500 enrolled